# 4SC

> 4SC is a VC fund in Planegg backing Health Care and Biotechnology. See 1 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Planegg, Germany
- Total investments: 1
- Last investment: Nov 2015
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/4sc-ag
- X (Twitter): https://www.twitter.com/4sc_ag
- Website: http://www.4sc.de/
- Facebook: https://www.facebook.com/pg/4SC-AG-226095544525585/

4SC is a VC fund in Planegg focused on Health Care and Biotechnology. 4SC discovers and develops targeted, small-molecule drugs for the treatment of cancer and autoimmune diseases in indications with high unmet medical needs. These drugs are intended to provide innovative treatment options that are more tolerable and efficacious, and provide a better quality of life.

## Contacts

5 contacts available for 4SC. Shizune tracks 3 team members at 4SC. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/4sc?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 1 | 100% |
| Biotechnology | 1 | 100% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Frank Hermann | Chief Development Officer | 0 | https://shizune.co/investors/profile/frank-hermann-a529 |
| Jason Loveridge | Chief Executive Officer | 0 | https://shizune.co/investors/profile/jason-loveridge |
| Susanne Danhauser-Riedl | Chief Medical Officer | 0 | https://shizune.co/investors/profile/susanne-danhauser-riedl |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Panoptes Pharma | Panoptes is a privately held biotech company focused on developing small molecule based therapies for the treatment of severe eye diseases with high unmet medical need. Panoptes is located in the city center of Vienna, Austria.The development of Panoptes´ clinical candidate PP-001 focuses on a new treatment for autoimmune uveitis, a disease whichis one of the major causes of blindness. As a second indication, adenoviral conjunctivitis will be pursued, a disease for which to date, no treatment is available. Due to its unique mode of action, PP-001 has therapeutic potential for additional inflammatory and viral indications.Panoptes has an experienced team of development experts with a proven track record of developing and commercializing innovative products. The team is developing a focused portfolio of high-performance small molecule products, with its lead clinical candidate PP-001 in preclinical development. |  | Seed | Nov 02, 2015 |  |

1 of 1 investments shown.

## Co-investors
- [Arax Capital Partners](https://shizune.co/investors/profile/arax-capital-partners) — VC Fund, 1 deal together
- [aws Gründungsfonds](https://shizune.co/investors/profile/aws-grnderfonds) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [Speedinvest](https://shizune.co/investors/profile/speedinvest) — VC Fund
- [tecnet equity](https://shizune.co/investors/profile/tecnet-equity) — VC Fund
- [aws Gründungsfonds](https://shizune.co/investors/profile/aws-grnderfonds) — VC Fund

## Featured in investor lists
- [Biotechnology VC Funds in Austria](https://shizune.co/investors/biotechnology-vc-funds-austria)
- [Biotech Investors in Austria](https://shizune.co/investors/biotech-investors-austria)
- [Biotech VC Funds in Austria](https://shizune.co/investors/biotech-vc-funds-austria)

## FAQ

### What does 4SC invest in?

4SC invests primarily in Health Care and Biotechnology startups, most often at Seed stage. Most of the 1 investments tracked by Shizune back companies in Austria. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact 4SC?

Public channels for 4SC include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at 4SC?

The team at 4SC includes Frank Hermann (Chief Development Officer), Jason Loveridge (Chief Executive Officer) and Susanne Danhauser-Riedl (Chief Medical Officer). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co